MDGL Q3 2022 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$80M

Net Income

-$81M

EPS (Diluted)

$-4.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$159M

Total Liabilities

$148M

Stockholders' Equity

$11M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$80M	-$63M	-27.3%
Net Income	-$81M	-$63M	-28.7%